Guardion Health Sciences Announces Approval by Stockholders of Proposed Sale of Viactiv Business
Adjourns Special Meeting to May 31, 2024 in order to Solicit Additional Proxies in Support of its Plan of Liquidation and Dissolution
HOUSTON, TEXAS, May 23, 2024 (GLOBE NEWSWIRE) — Guardion Health Sciences, Inc. (Nasdaq:GHSI) (“Guardion” or the “Company”), a clinical nutrition company that offers a portfolio of science-based, clinically-supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients, announced today that its stockholders approved the previously announced sale of its Viactiv business at a special meeting (the “Meeting”) held earlier today. Following this approval, the Company then adjourned the Meeting to 11:00 a.m. Central Time on May 31, 2024 in order to give the Company’s management additional time to solicit proxies from its stockholders of record on April 5, 2024 to vote in favor of the proposal to adopt the Company’s Plan of Liquidation and Dissolution, as described in the Company’s definitive proxy statement filed with the United States Securities and Exchange Commission on April 8, 2024. The Company needs to obtain approval from a majority of its shares of common stock issued and outstanding for the proposal to pass.